Etern
Latest round
- Series B
Last raised
- Jun 2026
Total raised
- $14M
Investors
- 11
About Etern
, trading as Etern, operates as a drug developer mainly engaged in the research and development of small molecule drugs targeting protein liquid-liquid phase separation. Jidong Zhu, the co-founder of the company, has worked at Novartis and served as an independent principal investigator in the Chinese Academy of Sciences for 7 years. In October 2021, it won the Excellent Enterprise Award of the 10th China Innovation & Entrepreneurship Competition Biomedical Section. The company provides innovative drugs for tumor targets and related solutions for tumor treatment. The products include the SRC homology-2 domain-containing phosphatase 2 (SHP2) allosteric inhibitor ET0038 and protein liquid-liquid phase separation (LLPS) technology platform. The company adopts structural biology and molecular biology mechanisms. The company generates revenue by developing small-molecule therapeutics through its LLPS-based drug discovery platform and by providing related drug research and development services. In the future, the company will continue to delve into cutting-edge LLPS underlying technologies, accelerate the global clinical development and registration of its core pipelines, and continuously produce world-first-in-class original drugs. At the same time, it will deepen the technological synergy between LLPS and AI-driven drug development, based on rigorous medical drug research and development, and expand into the consumer healthcare sector to precisely meet the public's increasingly sophisticated needs for high-end anti-aging and health maintenance.
Who invested in Etern
11 investors across 5 rounds
See all investors in Etern
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Etern
Who invested in Etern?
Etern has 11 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Etern raised?
Etern has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Etern last raise money?
Etern's most recent round on record is a Series B, in Jun 2026.
What does Etern do?
, trading as Etern, operates as a drug developer mainly engaged in the research and development of small molecule drugs targeting protein liquid-liquid phase separation.
Where is Etern headquartered?
Etern is headquartered in Shanghai, China.
Which VCs invest in companies like Etern?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at Etern's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Etern? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.